differently, possibly with an emphasis on earlier treatment." Dr. Welk's co-author was Andrew McClure, MSc.The researchers analyzed data on 3,046 men aged 50 years or with moderate to severe LUTS from a previous clinical trial . Participants were randomly assigned to active treatment with medications for LUTS—the alpha-1 blocker doxazosin, the 5-alpha reductase inhibitor finasteride, or a combination of the two—or inactive placebo treatment.
"Improvement in male LUTS was associated with a reduced risk of death," the researchers write. For each one-point reduction in symptom score, the relative likelihood for death decreased by 4%. Greater symptom reductions were linked to greater reductions risk of death: hazard ratio decreased by 12% with a three-point reduction in symptom score and by 35% with a 10-point reduction in LUTS.
Lower urinary tract symptoms such as weak stream and frequent nighttime urination are very common in older men. Previous studies have linked moderate to severe LUTS to an increased risk of death. The new study is the first to focus on whether improvement in male LUTS may reduce this excess risk of death.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: nottslive - 🏆 96. / 52 Read more »
Source: EchoWhatsOn - 🏆 74. / 59 Read more »
Source: nottslive - 🏆 96. / 52 Read more »
Source: MetroUK - 🏆 13. / 82 Read more »
Source: leedslivenews - 🏆 118. / 51 Read more »
Source: BBCWestScot - 🏆 85. / 53 Read more »